Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)

Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)

Abstract Iron‐deficiency anemia is a potent stimulator of the phosphaturic hormone Fibroblast growth factor‐23 (FGF23). Anemia, elevated FGF23, and elevated serum phosphate are significant mortality risk factors for patients with chronic kidney disease (CKD). However, the contribution of anemia to o...

Full description

Bibliographic Details
Main Authors: Megan L. Noonan, Erica L. Clinkenbeard, Pu Ni, Elizabeth A. Swallow, Samantha P. Tippen, Rafiou Agoro, Matthew R. Allen, Kenneth E. White
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Physiological Reports
Subjects:
CKD
EPO
FGF‐23
HIF‐PHDi
phosphate
Online Access:https://doi.org/10.14814/phy2.14434

Internet

https://doi.org/10.14814/phy2.14434

Similar Items